| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -18,802 | -10,998 |
| Stock-based compensation expense | 2,349 | 1,724 |
| Depreciation | 41 | 29 |
| Change in the fair value of warrant liability | -177 | -1,777 |
| Change in the fair value of promissory notes | -23 | -423 |
| Promissory note issuance costs | -336 | -335 |
| Transaction costs associated with warrants | 0 | 0 |
| Accretion of discount on short-term investment | 307 | 218 |
| Prepaid expenses and other current and non-current assets | -281 | 11 |
| Accounts payable | -884 | -88 |
| Accrued expenses and other liabilities | 860 | -121 |
| Net cash used in operating activities | -16,326 | -11,548 |
| Purchase of investments | 15,420 | 13,940 |
| Maturity of investments | 17,845 | 12,845 |
| Purchases of property and equipment | 22 | 14 |
| Net cash provided by investing activities | 2,403 | -1,109 |
| Proceeds from issuance of common stock, net of issuance costs | 8 | 8 |
| Proceeds from exercise of stock options | 25 | 0 |
| Proceeds from issuance of promissory note payable, net | 9,664 | 9,664 |
| Proceeds from issuance of common stock from atm facility, net of issuance costs | 1,761 | 968 |
| Net cash provided by financing activities | 11,458 | 10,640 |
| Net (decrease) increase in cash and cash equivalents | -2,465 | -2,017 |
| Cash and cash equivalents at beginning of period | 7,935 | - |
| Cash and cash equivalents at end of period | 5,470 | - |
CalciMedica, Inc. (CALC)
CalciMedica, Inc. (CALC)